LAT1、CD98hc在胃癌组织中表达与临床病理特征的关系

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (12): 1361-1366.

LAT1、CD98hc在胃癌组织中表达与临床病理特征的关系

史良会^1,2, 张才全¹, 彭小壮²

¹重庆医科大学第一附属医院胃肠外科,重庆 400016;
²皖南医学院附属弋矶山医院胃肠外科,芜湖 241000,安徽

收稿日期:2011-11-07 修回日期:2011-11-22 出版日期:2011-12-26 发布日期:2012-01-07
通讯作者: 张才全,通信作者,男,教授,博士生导师,研究方向:胃肠道肿瘤研究。Tel: 023-89011172 E-mail: zhangyu0323@21cn.com
作者简介:史良会,男,在读博士,副教授,研究方向:胃肠道肿瘤基础与临床研究。Tel: 0553-5739038 E-mail: slh1020@163.com
基金资助:
安徽省高校自然科学研究基金重点项目(KJ2011A264)

Relationship between the expression of LAT1,CD98hc and clinical pathological characteristics of gastric carcinoma

SHI Liang-hui^1,2, ZHANG Cai-quan¹, PENG Xiao-zhuang²

¹Department of Gastrointestinal Surgery, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China;
²Department of Gastrointestinal Surgery, Affiliated Yijishan Hospital, Wannan Medical College, Wuhu 241000, Anhui, China

Received:2011-11-07 Revised:2011-11-22 Online:2011-12-26 Published:2012-01-07

摘要/Abstract

摘要： 目的: 探讨L型氨基酸转运载体1(L-type amino acid transporter-1,LAT1)、CD98hc在胃癌中的表达及其与胃癌临床病理特征的关系。方法: 采用逆转录多聚酶链反应(RT-PCR)方法和免疫组织化学方法检测45例胃癌组织及45例癌旁正常组织中LAT1、CD98hc、Ki67表达。结果: RT-PCR检测显示胃癌组织中LAT1、CD98hc的表达显著高于癌旁正常组织(P<0.05);免疫组化结果显示,LAT1在胃癌组织和癌旁组织中表达率分别为64.4%和6.67%(P<0.01); CD98hc在胃癌组织和癌旁组织中的表达率分别为60.0%和22.2%(P<0.01);LAT1、CD98hc的表达在低分化组显著高于高中分化组(P<0.05);肿瘤大小≥5 cm 组显著高于＜5 cm组;在Ⅰ～Ⅱ期、淋巴结无转移组LAT1、CD98hc的表达明显比Ⅲ～Ⅳ期、淋巴结转移组低(P<0.01); LAT1、CD98hc与Ki67的表达水平均呈正相关(P<0.01)。结论: 胃癌组织中LAT1、CD98hc具有高表达率,且表达具有高度肿瘤特异性,提示LAT1、CD98hc可能在胃癌的生长与转移中有非常重要的作用。

关键词: LAT1, CD98hc, 胃癌, RT-PCR, 免疫组织化学

Abstract: AIM: To investigate the expression of L-type amino acid transporter-1(LAT1), CD98hc in gastric carcinoma and elucidate the relationship between their overexpression and clinical pathological characteristics.METHODS: The expression of LAT1, CD98hc and Ki67 in 45 cases of gastric cancer, 45 cases of adjacent normal gastric tissue were detected by using semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry.RESULTS: RT-PCR analysis showed that the expression of LAT1, CD98hc mRNA in gastric carcinoma tissues were significantly higher than those in adjacent normal gastric tissues(P<0.05). Immunohistochemistry showed that the positive rate of LAT1 accounted for 64.4% (29/45) in gastric carcinoma, and 6.67% in adjacent normal gastric tissues (P<0.01). The positive expression rate of CD98hc was 60.0% in gastric carcinoma tissues, and 22.2% in adjacent normal gastric tissues (P<0.01). The expression of LAT1, CD98hc in poorly differentiated gastric carcinoma, stage Ⅲ-Ⅳ were significantly higher those in well differentiated gastric carcinoma, stage Ⅰ-Ⅱ(P<0.05). In gastric cancer with lymph metastasis, tumor size ≥5 cm, their expression were significantly higher than that in gastric cancer without lymph metastasis, tumor size ＜5 cm(P<0.05). The higher expression of LAT1, CD98hc were positive correlated to Ki67 in gastric carcinoma (P<0.01).CONCLUSION: LAT1, CD98hc specifically highly express in gastric carcinoma. The abnormal expression may play an important role in the carcinogenesis and metastasis of gastric carcinoma.

Key words: LAT1, CD98hc, Gastric carcinoma, RT-PCR, Immunohistochemistry

中图分类号:

R573

史良会, 张才全, 彭小壮. LAT1、CD98hc在胃癌组织中表达与临床病理特征的关系[J]. 中国临床药理学与治疗学, 2011, 16(12): 1361-1366.

SHI Liang-hui, ZHANG Cai-quan, PENG Xiao-zhuang. Relationship between the expression of LAT1,CD98hc and clinical pathological characteristics of gastric carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1361-1366.

参考文献

[1] Yanagida O, Kanai Y, Chairoungdua A,et al.Human L-type amino acid trans- porter 1(LAT1):characterization of function and expression in tumor cel1 lines[J].Biochim Biophys Acta,2001,1514(2):291-302.
[2] Asano S,Kameyama M,Oura A,et al.L-type amino acid transporter-1 expressed in human astrocytomas,U343MGa[J].Biol Pharm Bull,2007,30(3):415-422.
[3] Broer A,Wagner CA,Lang F,et al.The heterodimeric amino acid trans- porter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glu- tamine[J].Biochem J,2000,349(Pt3):787-795.
[4] Broer S,Wagner CA.Structure-function relationships of heterodimeric amino acid transporters[J].Cell Biochem Biophys,2002,36(2/3):155-168.
[5] Jain-Vakkalagadda B, Dey S, Pal D, et al. Identification and functional characteriza -tion of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea[J]. Invest Ophthalmol Vis Sci, 2003,44 (7):2919-2927.
[6] Kanai Y, Segawa H, Mivamoto K, et al.Expression cloning and character- rization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen(CD98)[J].J Biol Chem,1998,273(37):23629-23632.
[7] Bodoy S, Martin L, Zorzano A, et al.Identification of LAT4,a novel amino acid transporter with system L activity[J].J Biol Chem,2005,280(12): 12002-12011.
[8] Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer:partners in crime[J] ? Seminars Cancer Biol, 2005, 15(4): 254-266.
[9] Ohkame H, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models[J]. J Surg Oncol,2001,78(4): 265-271.
[10] Tamai S, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size[J]. Cancer Detect Prev, 2001,25(5): 439-445.
[11] Nakanishi K, Matsuo H, Kanai Y, et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung[J]. Virchows Arch, 2006,448(2):142-150.
[12] Ohkame H, Masuda H, Ishii Y, et al. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models[J]. J Surg Oncol, 2001,78(4):265-271.
[13] Lin J, Raoof DA,Thomas DG,et a1.L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma[J]. Neoplasia,2004,6(1):74-84.
[14] Baniasadi S, Chairoungdua A, Iribe Y, et a1.Gene expression profiles in T24 human bladder carcinoma cells by inhibiting an L-type amino acid transporter,LAT1[J].Arch Pharm Res,2007,30(4): 444-452.

[1]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[2]	封壮壮, 宋瑞平, 豆鹏程, 陈心怡, 左娇娇, 舒劲. 基于mTOR/Beclin1/LC3信号轴探讨制萎扶胃丸对胃癌前病变大鼠胃窦组织自噬的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 361-370.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[5]	江玉华, 支慧, 卢林明, 田大皓, 王晓庆, 葛钰, 谢尚富, 王琪. 皖南蝮蛇毒抑瘤组分-I逆转原代胃癌相关成纤维细胞促癌作用[J]. 中国临床药理学与治疗学, 2021, 26(4): 389-394.
[6]	帕孜来提·亚森, 袁浩, 路红, 郑亚, 王玉平, 周永宁. 胃癌靶向治疗药物临床实验研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 454-461.
[7]	吴懿, 朱阿考, 单毓强, 应荣超, 金慧成. 白藜芦醇调控miR-409-3p/FKBP14抑制胃癌细胞BGC823恶性进程[J]. 中国临床药理学与治疗学, 2020, 25(9): 968-975.
[8]	田大皓, 卢林明, 支慧, 周珏, 王晓庆, 江玉华. 皖南蝮蛇毒抑瘤组分-Ⅰ对人原代胃癌细胞增殖的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 505-511.
[9]	沈成，杨年钊，王明海，吴立胜，朱志强. RNA甲基化酶NSUN2对胃癌细胞侵袭和迁移的影响及机制研究[J]. 中国临床药理学与治疗学, 2020, 25(4): 380-386.
[10]	刘宇佳，李莉，胡晓平，钟里科，李晶晶，黄萍，张轶雯. 基于生物信息学的胃癌特征基因网络关键节点及预后关联分析[J]. 中国临床药理学与治疗学, 2019, 24(8): 852-859.
[11]	滕晓晶，董学妍，王智毅，余道军，王贤军. 扶正康复合剂联合顺铂抑制胃癌SGC7901细胞荷瘤裸鼠肿瘤增殖作用的实验研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 744-749.
[12]	董金良. 每周脂质体紫杉醇联合替吉奥对老年晚期胃癌患者血清肿瘤标志物与可溶性E-钙黏连蛋白的影响[J]. 中国临床药理学与治疗学, 2019, 24(7): 805-809.
[13]	戴蕾，罗灵和，吴黎艳，王刚，费保莹. miR-222、MBD2在胃癌患者中的表达及对铂类化疗敏感性的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 623-629.
[14]	张腾跃，杨广山，马克龙，范平生. 抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 433-439.
[15]	李玉琴，王凯，敖丽，鲁晓岚，施建平. miR-142-5p通过DNA甲基转移酶1抑制胃癌细胞增殖迁移的机制研究[J]. 中国临床药理学与治疗学, 2019, 24(12): 1328-1334.